Shopify Inc.
NYSE

REAL TIME PRICE

EXTENDED HOURS
Day’s Range -
52 Week Range -
Prepackaged Software

JMP Securities Upgrades Shopify (SHOP)

2024-05-10 24:18
US

Fintel reports that on May 9, 2024, JMP Securities upgraded their outlook for Shopify (NYSE:SHOP) from Market Perform to Market Outperform.

Analyst Price Forecast Suggests 34.85% Upside

As of May 8, 2024, the average one-year price target for Shopify is 84.59. The forecasts range from a low of 60.60 to a high of $110.25. The average price target represents an increase of 34.85% from its latest reported closing price of 62.73.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Shopify is 8,356MM, an increase of 12.72%. The projected annual non-GAAP EPS is 0.12.

What is the Fund Sentiment?

There are 1,803 funds or institutions reporting positions in Shopify. This is an increase of 117 owner(s) or 6.94% in the last quarter. Average portfolio weight of all funds dedicated to SHOP is 0.60%, an increase of 5.54%. Total shares owned by institutions increased in the last three months by 4.14% to 984,869K shares. SHOP / Shopify Inc. Put/Call Ratios The put/call ratio of SHOP is 0.78, indicating a bullish outlook.

What are Other Shareholders Doing?

SHOP / Shopify Inc. Shares Held by Institutions

Baillie Gifford holds 61,387K shares representing 4.76% ownership of the company. In its prior filing, the firm reported owning 64,165K shares , representing a decrease of 4.52%. The firm decreased its portfolio allocation in SHOP by 6.97% over the last quarter.

Capital World Investors holds 39,425K shares representing 3.06% ownership of the company. In its prior filing, the firm reported owning 30,635K shares , representing an increase of 22.29%. The firm increased its portfolio allocation in SHOP by 64.94% over the last quarter.

Capital Research Global Investors holds 38,257K shares representing 2.97% ownership of the company. In its prior filing, the firm reported owning 42,832K shares , representing a decrease of 11.96%. The firm increased its portfolio allocation in SHOP by 13.93% over the last quarter.

Jpmorgan Chase holds 29,861K shares representing 2.32% ownership of the company. In its prior filing, the firm reported owning 29,184K shares , representing an increase of 2.27%. The firm increased its portfolio allocation in SHOP by 27.20% over the last quarter.

Price T Rowe Associates holds 28,257K shares representing 2.19% ownership of the company. In its prior filing, the firm reported owning 31,997K shares , representing a decrease of 13.23%. The firm increased its portfolio allocation in SHOP by 15.59% over the last quarter.

Shopify Background Information
(This description is provided by the company.)

Shopify is a leading global commerce company, providing trusted tools to start, grow, market, and manage a retail business of any size. Shopify makes commerce better for everyone with a platform and services that are engineered for reliability, while delivering a better shopping experience for consumers everywhere. Headquartered in Ottawa, Canada, Shopify powers over one million businesses in more than 175 countries and is trusted by brands such as Allbirds, Gymshark, PepsiCo, Staples and many more.

Stories by George Maybach

Jefferies Initiates Coverage of Nucor (NUE) with Hold Recommendation
Fintel reports that on May 20, 2024, Jefferies initiated coverage of Nucor (NYSE:NUE) with a Hold recommendation.

JP Morgan Upgrades HUYA Inc. - Depositary Receipt () (HUYA)
Fintel reports that on May 20, 2024, JP Morgan upgraded their outlook for HUYA Inc.

Jefferies Initiates Coverage of Cleveland-Cliffs (CLF) with Buy Recommendation
Fintel reports that on May 20, 2024, Jefferies initiated coverage of Cleveland-Cliffs (NYSE:CLF) with a Buy recommendation.

Jefferies Initiates Coverage of AZZ (AZZ) with Buy Recommendation
Fintel reports that on May 20, 2024, Jefferies initiated coverage of AZZ (NYSE:AZZ) with a Buy recommendation.

Piper Sandler Upgrades Globus Medical (GMED)
Fintel reports that on May 20, 2024, Piper Sandler upgraded their outlook for Globus Medical (NYSE:GMED) from Neutral to Overweight.